Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress
Redox Biology · 2024-02 · 69 · 103010
DOI: 10.1016/j.redox.2023.103010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Redox Biology, 2024-02. Verfasst von Weijuan Cai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang, 524000, China. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Mitochondrial Diseases, Diabetes Mellitus, Benzhydryl Compounds. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Science and Technology Research Fund of Guangdong Province, Central People's Hospital of Zhanjiang Startup Project of Doctor Scientific Research.
Abstract (Originalsprache)
Ketone bodies are considered as an alternative energy source for diabetic cardiomyopathy (DCM) and can improve the energy supply of the heart muscle, suggesting that it may be an important area of research and development as a therapeutic target for DCM. Cumulative cardiovascular trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in diabetic populations. Whether SGLT2 inhibitors improve DCM by enhancing ketone body metabolism remains and whether they help prevent oxidative damage remains to be clarified. Here, we present the combined results of nine GSE datasets for diabetic cardiomyopathy (GSE215979, GSE161931, GSE145294, GSE161052, GSE173384, GSE123975, GSE161827, GSE210612, and GSE5606). We found significant up-regulated gene 3-hydroxymethylglutaryl CoA synthetase 2 (HMGCS2) and down-regulated gene 3-hydroxybutyrate dehydrogenase (BDH1) and 3-oxoacid CoA-transferase1 (OXCT1), respectively. Based on the analysis of the constructed protein interaction network, it was found that HMGCS2 was in the core position of the interaction network. In addition, Gene ontology (GO) enrichment analysis mainly focused on redox process, acyl-CoA metabolic process, catalytic activity, redox enzyme activity and mitochondria. The activity of HMGCS2 in DCM heart was increased, while the expression of ketolysis enzymes BDH1 and OXCT1 was inhibited. In vivo, Empagliflozin (Emp) treated DCM group significantly decreased ventricular weight, myocardial cell cross-sectional area, and myocardial fibrosis. In addition, Emp further promoted the activity of BDH1 and OXCT1, increased the utilization of ketone bodies, further promoted the activity of HMGCS2 in DCM, and increased the synthesis of ketone bodies, prevented mitochondrial breakage and dysfunction, increased myocardial ATP to provide sufficient energy, inhibited oxidative stress and apoptosis of cardiac cells ex vivo, and improved the myocardial dysfunction of DCM. Emp can improve mitochondrial dysfunction in diabetic cardiomyopathy by regulating ketone body metabolism and oxidative stress. These findings provide a theoretical basis for evaluating Emp as a treatment for DCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang, 524000, China.
- Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao Binhai University, Qingdao, 266404, China.
- Department of Endocrinology and Metabolism, Central People's Hospital of Zhanjiang, Zhanjiang, 524000, China.
- Department of Endocrinology and Metabolism, Central People's Hospital of Zhanjiang, Zhanjiang, 524000, China. Electronic address: cwj_yl@163.com.
Förderung
- Medical Science and Technology Research Fund of Guangdong Province
- Central People's Hospital of Zhanjiang Startup Project of Doctor Scientific Research
Zitieren
APA
Cai, W., Chong, K., Huang, Y., Huang, C., & Yin, L. (2024). Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox Biology, 69, 103010. https://doi.org/10.1016/j.redox.2023.103010
Vancouver
Cai W, Chong K, Huang Y, Huang C, Yin L. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox Biology. 2024;69:103010. doi:10.1016/j.redox.2023.103010
BibTeX
@article{Cai2024,
author = {Cai, Weijuan and Chong, Kunying and Huang, Yunfei and Huang, Chun and Yin, Liang},
title = {Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress},
journal = {Redox Biology},
year = {2024},
volume = {69},
pages = {103010},
doi = {10.1016/j.redox.2023.103010}
}
EUVIMED